Formycon

Formycon Intangible Assets

The Intangible Assets of Formycon (FYB.DE) as of Nov 22, 2026 is 444.12 M EUR. In the previous year, Intangible Assets was 508.40 M EUR — a change of -12.64% (lower).

Intangible Assets

444.12 MEUR

YoY

-12.64%

Last updated:

Intangible Assets of Formycon is 2024 444.12 M EUR. Intangible Assets of Formycon was 2023 508.40 M EUR. It decreases by -12.64% lower compared to the previous year.

The Formycon Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2017
109,400.00 EUR
Jan 1, 2018
175,700.00 EUR
Jan 1, 2019
198,200.00 EUR
Jan 1, 2020
271,000.00 EUR
Jan 1, 2021
727,000.00 EUR
Jan 1, 2022
488.44 M EUR
Jan 1, 2023
508.40 M EUR
Jan 1, 2024
444.12 M EUR
The Formycon Intangible Assets history
YEARIntangible AssetsYoY
444.12 MEUR-12.64%
508.40 MEUR+4.09%
488.44 MEUR+67,085.56%
727,000.00EUR+168.27%
271,000.00EUR+36.73%
198,200.00EUR+12.81%
175,700.00EUR+60.60%
109,400.00EUR+31.33%
83,300.00EUR+19.34%
69,800.00EUR-41.88%
120,100.00EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Formycon Stock analysis

What does Formycon do? Formycon AG is a German biotechnology company that was founded in 2010 in Martinsried near Munich. The company's history mainly began with the development of an innovative technology concept that allows for the cost-effective and efficient production of biosimilars. The market entry started in 2017 with the launch of the first proprietary biosimilar on the European market. The core business of Formycon AG is the production and distribution of biosimilars. These are biological drugs that have a similar structure and efficacy to already approved original drugs. The development of biosimilars is complex due to the elaborate manufacturing process and high-quality assurance requirements, requiring innovative ideas and technologies. Formycon AG has developed its innovative platform technology, FORMYCON® NEXT LEVEL, which allows the company to cost-effectively produce large quantities of proteins used in cancer therapy, immunotherapy, and the treatment of autoimmune diseases. Formycon AG is divided into various divisions, including research and development, production, and distribution. In research and development, new biosimilars and other innovative technologies are developed to further improve production processes. Production takes place in a dedicated biotechnological production facility in Roth near Nuremberg, where up to eight different medications can be produced simultaneously. In the distribution sector, Formycon AG collaborates with partners who market and distribute the biosimilars in different countries. The company operates internationally, with a presence in Europe, the USA, and Asia. The biosimilars produced by Formycon AG are a cost-effective alternative to the existing original drugs. The products are used in the fields of oncology, immunology, and ophthalmology, offering patients a chance to receive effective therapy at an affordable price. Successful marketing and high demand contribute to positive company development. In 2020, Formycon AG generated a revenue of 25 million euros and currently employs approximately 150 staff members. An example of a biosimilar produced by Formycon AG is the drug FYB202, which is used for the treatment of breast, ovarian, and salivary gland cancer. It is a replica of the breast cancer medication Herceptin®, developed and distributed by the Swiss company Roche. The FYB202 biosimilar has shown in clinical studies that it is similarly effective as Herceptin® but represents a more cost-effective alternative for patients. Overall, Formycon AG pursues a sustainable business model with a focus on the development of cost-effective biosimilars. The innovative technology and focus on cost-effective production enable the company to achieve a strong market presence and offer an effective alternative to conventional drugs. Formycon is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Formycon stock

Intangible Assets of Formycon is 444.12 M EUR in 2024.

Intangible Assets of Formycon changed from 508.40 M EUR to 444.12 M EUR, representing a -12.64% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets Formycon since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's Formycon historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Formycon

All Key Metrics — Formycon